AZN.L - AstraZeneca PLC

LSE - LSE Delayed price. Currency in GBp
+113.00 (+1.59%)
At close: 4:53PM BST
Stock chart is not supported by your current browser
Previous close7,103.00
Bid7,161.00 x 0
Ask7,169.00 x 0
Day's range6,963.00 - 7,240.00
52-week range5,626.00 - 8,227.88
Avg. volume2,717,764
Market cap94.689B
Beta (5Y monthly)0.36
PE ratio (TTM)70.33
Earnings dateN/A
Forward dividend & yield2.18 (3.07%)
Ex-dividend date27 Feb 2020
1y target estN/A
Press releases
  • Business Wire

    BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

    Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed BRILINTA (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus BRILINTA in high-risk coronary patients.

  • Business Wire

    FARXIGA Phase III DAPA-CKD Trial Will Be Stopped Early After Overwhelming Efficacy in Patients With Chronic Kidney Disease

    The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for FARXIGA (dapagliflozin) in patients with chronic kidney disease (CKD) will be stopped early following a recommendation from an independent Data Monitoring Committee (DMC) based on its determination of overwhelming efficacy.

  • Business Wire

    IMFINZI (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer

    AstraZeneca today announced that IMFINZI® (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide and either carboplatin or cisplatin (platinum-etoposide).

  • Business Wire

    FARXIGA reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark Phase III DAPA-HF trial

    New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s FARXIGA (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo, in patients with heart failure with reduced ejection fraction (HFrEF), irrespective of their background therapy (i.e. other medications for heart failure).

  • EQS Group

    Hardman & Co Research: Global Pharmaceuticals: 2018 industry sales

    Hardman & Co Research 09-Apr-2019 / 16:10 GMT/BST * * *Hardman & Co Research: Global Pharmaceuticals: 2018 industry salesOver the last few weeks, most of the multi-national pharmaceutical companies have reported results for 2018, which has given us the opportunity to update our industry statistics and drug database. This report provides the first publication of global and US rankings of the top 15 drug companies for 2018. Comparisons are made with historical data to show how different company strategies have evolved. In addition, analysis has been provided for the evolution of therapeutic biopharmaceutical drugs, which saw sales rise 7.5% to $219bn, representing 25% of the market, and driven by growth in antibody-derived drugs.Companies (Ticker ISIN) mentioned in this report: AbbVie (ABBV US00287Y1091), Amgen (AMGN US0311621009), AstraZeneca (AZN GB0009895292), Bayer (BAYGN DE000BAY0017), Bristol-Myers Squibb (BMY US1101221083), Celgene (CELG US1510201049), Gilead Sciences (GILD US3755581036), GlaxoSmithKline (GSK GB0009252882), Johnson & Johnson (JNJ US4781601046), Eli Lilly (LLY US5324571083), Merck & Co (MRK US58933Y1055), Novartis (NOVN CH0012005267), Novo Nordisk (NOVO DK0060534915), Pfizer (PFE US7170811035), Roche (ROG CH0012032113), Sanofi (SAN FR0000120578), Takeda (4502 JP3463000004), Teva (TEVA US8816242098). Please click here for the full report: contact us: Hardman & Co 35 New Broad Street London EC2M 1NH Follow us on Twitter @HardmanandCo Contacts: Martin Hall +44 20 7194 7632 Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more